Ziegler v. GW Pharmaceuticals, PLC

CourtDistrict Court, S.D. California
DecidedMarch 25, 2024
Docket3:21-cv-01019
StatusUnknown

This text of Ziegler v. GW Pharmaceuticals, PLC (Ziegler v. GW Pharmaceuticals, PLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ziegler v. GW Pharmaceuticals, PLC, (S.D. Cal. 2024).

Opinion

1 2 3 4 5 6

7 UNITED STATES DISTRICT COURT 8 SOUTHERN DISTRICT OF CALIFORNIA

9 KURT ZIEGLER and DANIEL BRADY, Case No. 21-cv-1019-BAS-MSB 10 Individually and on Behalf of All Others Similarly Situated, ORDER GRANTING FINAL 11 APPROVAL AND DISMISSING Plaintiffs, 12 CASE WITH PREJUDICE v. (ECF Nos. 47, 48) 13 GW PHARMACEUTICALS, PLC,

JUSTIN GOVER, GEOFFREY GUY, 14 CABOT BROWN, DAVID GRYSKA, 15 CATHERINE MACKEY, JAMES NOBEL, ALICIA SECOR and LORD 16 WILLIAM WALDEGRAVE, 17 Defendants. 18 19 Now pending before the Court is a Motion for Final Approval of a class action 20 settlement. (ECF No. 47.) Having reviewed the briefing and had the benefit of oral 21 argument on December 11, 2023, the Court GRANTS Lead Plaintiffs’ Motion for Final 22 Approval of the proposed class action. 23 I. BACKGROUND 24 The factual and procedural background of this action is discussed in detail in the 25 Court’s Preliminary Approval Order and is incorporated by reference here. (ECF No. 44 26 at 1:26–3:9.) 27 28 1 II. SETTLEMENT OVERVIEW 2 Although the Court also previously described the Settlement in its Preliminary 3 Approval Order, the Court recounts its key aspects here. 4 Class definition. The Settlement Class is defined as follows: 5 all record holders and all beneficial holders of GW American Depositary Shares (“ADSs”) who purchased, sold, or held such 6 ADSs at any time during the period from and including March 7 10, 2021, the record date for voting on the Merger, through and including May 5, 2021, the date the Merger closed, including any 8 and all of their respective predecessors, successors, trustees, 9 executors, administrators, estates, legal representatives, heirs, assigns and transferees. Excluded from the Settlement Class are 10 (i) Defendants; (ii) members of the immediate families of each 11 Defendant; (iii) GW’s subsidiaries and affiliates; (iv) any entity in which any defendant has a controlling interest; (v) the legal 12 representatives, heirs, successors, administrators, executors, and 13 assigns of each defendant, in their capacity as such; and (vi) any persons or entities who properly exclude themselves by filing a 14 valid and timely request for exclusion. 15 16 (Settlement Agreement, ECF No. 47-3 at 11:4–15.) All Settlement Class Members who 17 have not opted out of the Settlement are bound by the release set forth in the Settlement 18 Agreement. (Id. at 13:2–23.) No objections to the settlement have been received and only 19 one class member has submitted a request for exclusion. (ECF No. 47-1 at 19:4–6; ECF 20 No. 47-2 ¶ 12.) 21 Settlement amount. The Settlement Agreement requires Defendant GW 22 Pharmaceuticals (“GW”) to establish a Settlement Fund of $7,500,000 to be allocated on a 23 pro rata basis, based on the number of GW ADSs Settlement Class Members each held, to 24 Settlement Class Members minus any Court-approved deductions and expenses (including 25 attorneys’ fees, litigation costs, and individual service awards for lead plaintiffs Ziegler 26 and Brady). (Id. at 1:13–18, 23:24–26.) Class Counsel seek an award of attorneys’ fees in 27 the amount of $2,583,333.31 plus reimbursement of Lead Counsel’s costs and expenses in 28 the amount of $33,513.97. (ECF No. 48-1 at 1:12–13.) The total amount for attorneys’ 1 fees and costs requested is $2,616,847.28. Finally, the lead plaintiffs seek service awards 2 for serving as class representatives pursuant to 15 U.S.C. § 78u-4(a)(4). (ECF No. 48-11 3 ¶ 2; ECF No. 48-12 ¶ 2.) Both Ziegler and Brady seek $5,000 each for the approximately 4 30 hours dedicated to this action, which is presumptively reasonable. 5 If all holders of the approximately 30,723,630 ADSs in the Settlement Class 6 submitted a valid and timely Proof of Claim and Release, the average distribution will be 7 ~$0.25 per ADS owned, prior to fees and costs. (ECF No. 47-1 at 24:19–23.) 8 Notice. Pursuant to the Preliminary Approval Order, the Claims Administrator 9 mailed the Notice by the Notice Date to all record holders and beneficial holders of GW 10 ADSs who purchased, sold, or held ADSs at any time during the Settlement Class Period 11 and also posted the Notice on the settlement website at www.gwsecuritieslitigation.com. 12 (ECF No. 47-2 ¶ 11.) Nearly 30,000 copies of the notice were mailed to potential 13 Settlement Class Members and nominees. (Id. ¶ 12.) In addition, Lead Counsel published 14 a Summary Notice via PRNewswire. (Id. ¶ 11.) 15 Defendants also timely provided Class Action Fairness Act (“CAFA”) notice on 16 March 28, 2023. (ECF No. 47-6, Ex. 4 ¶ 4.) Accordingly, the CAFA notice requirements 17 have been satisfied pursuant to 28 U.S.C. § 1715. 18 Distribution of the settlement fund. GW will deposit the Settlement Amount into 19 the Escrow Account, which is to be maintained by the Escrow Agent. (ECF No. 47-3 at 20 ¶ 2.1.) The Escrow Agent is in charge of managing and investing the Settlement Fund, but 21 only within the bounds of the Settlement Agreement. (Id. at ¶¶ 2.3–2.8.) The Escrow 22 Agent is authorized to pay up to $300,000 in connection with providing notice to Class 23 Members. (Id. at ¶ 2.7.) A Claims Administrator is in charge of calculating and 24 distributing payments from the Net Settlement Fund to the Class Members. (Id. at ¶ 5.1.) 25 The Settlement Fund will be distributed in the following order: (1) Notice and 26 Administration Costs; (2) Taxes and Tax Expenses; (3) Lead Counsel’s Fee and Expense 27 Award and Lead Plaintiff’s Service Awards; and (4) Net Settlement Fund to Authorized 28 Claimants. (ECF No. 47-1 at 23:4–7.) 1 Authorized Claimants must submit a Proof of Claim and Release by the date 2 specified in the Notice. If the Proofs of Claim are submitted late, Lead Counsel has the 3 discretion to accept those claims so long as they do not “materially delay distribution” of 4 payment to Authorized Claimants. (Id. at 22:22–24.) The Claims Administrator reviews 5 each Proof of Claim and Release, rejecting those that do not meet submission requirements 6 so long as the Claims Administrator has contacted the Claimant to attempt to remedy any 7 curable deficiencies and notify them they have a right for the Court to review any rejection. 8 (Id. at 22:25–23:1.) No distributions will be made to Authorized Claimants who would 9 otherwise receive a distribution of less than $10.00. (ECF No. 47-3 at 24:1–5.) 10 Scope of release. The class releases any and all claims that could have been asserted 11 or could be asserted in the future against Defendants, or Jazz Pharmaceuticals, and any and 12 all of their related parties. (Id. at 9:24–10:20.) These claims are considered released upon 13 the effective date of the Settlement Agreement “regardless of whether a Settlement Class 14 Member executes and delivers a Proof of Claim and Release.” (Id. at 19:24–10:20.) 15 Objections. In accordance with the Settlement Agreement, the Settlement 16 Administrator provided the notice required under CAFA to the attorneys general of 50 17 states, as well as the U.S. territories and the District of Columbia’s Corporate Counsel. 18 (ECF No. 48-6 ¶ 4.) No government entity has objected to the settlement or sought to 19 intervene. Further, no class member objections to the settlement have been received and 20 only one class member has submitted a request for exclusion. (ECF No. 47-1 at 19:4–6; 21 ECF No. 47-2 ¶ 12.) 22 III. ANALYSIS 23 The approval of a class-action settlement is a multi-step process. At the preliminary 24 approval stage, the court should grant such approval only if it is justified by the parties’ 25 showing that the court will likely be able to (1) “certify the class for purposes of judgment 26 on the proposal” and (2) “approve the proposal under Rule 23(e)(2).” Fed. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
United States v. Frank Locascio, and John Gotti
6 F.3d 924 (Second Circuit, 1993)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Martin Gonzalez, Sr. v. City of Maywood
729 F.3d 1196 (Ninth Circuit, 2013)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Infospace, Inc. Securities Litigation
330 F. Supp. 2d 1203 (W.D. Washington, 2004)
Robert Briseno v. Conagra Foods, Inc.
998 F.3d 1014 (Ninth Circuit, 2021)
Vizcaino v. Microsoft Corp.
290 F.3d 1043 (Ninth Circuit, 2002)
Knapp v. Art.com, Inc.
283 F. Supp. 3d 823 (N.D. California, 2017)
Cotton ex rel. McClure v. City of Eureka
889 F. Supp. 2d 1154 (N.D. California, 2012)
Ontiveros v. Zamora
303 F.R.D. 356 (E.D. California, 2014)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
Ziegler v. GW Pharmaceuticals, PLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ziegler-v-gw-pharmaceuticals-plc-casd-2024.